This inventor holds 1 USPTO granted patent and 4 published patent applications, plus 1 CIPO patent and 1 EPO patent. Top assignee: Johns Hopkins University. Active years: 2021.
Company Filing History:
Years Active: 2021
Title: Yumin Oh: Innovator in Autoimmune Fibrosis Treatment
Introduction
Yumin Oh is a prominent inventor based in Elkridge, MD (US). He has made significant contributions to the field of autoimmune diseases, particularly in the treatment of systemic sclerosis. His innovative approach focuses on utilizing death receptor agonists to combat this challenging condition.
Latest Patents
Yumin Oh holds a patent titled "Ameliorating systemic sclerosis with death receptor agonists." This patent outlines methods and compositions for treating and preventing autoimmune fibrosis, specifically systemic sclerosis (SSc; scleroderma). The method involves administering an effective amount of a death receptor agonist to a subject in need. Suitable agonists include tumor necrosis factor (TNF)-related apoptosis inducing ligand (TRAIL), agonistic death receptor antibodies, and their variants, analogues, or derivatives. The administration of these agonists effectively blocks fibroblast activation and reduces myofibroblasts, thereby preventing systemic sclerosis.
Career Highlights
Yumin Oh is affiliated with Johns Hopkins University, where he conducts research and develops innovative treatments for autoimmune diseases. His work has garnered attention for its potential to improve the quality of life for patients suffering from systemic sclerosis.
Collaborations
Yumin collaborates with esteemed colleagues, including Seulki Lee and Maureen Horton, to advance research in this critical area of medicine.
Conclusion
Yumin Oh's contributions to the treatment of systemic sclerosis through innovative patenting and research highlight his dedication to improving patient outcomes. His work exemplifies the impact of scientific innovation in addressing complex medical challenges.